** Analysts at Jefferies say several factors have the potential to lead to an upside for Integral Diagnostics' IDX.AX FY26 EBITDA estimates
** Brokerage says potential factors include upgrading of Partial to Full MRI Licences, which could drive MRI volumes, as well as lung cancer screening
** Jefferies maintains PT at A$3.60/shr and "buy" rating for stock
** IDX has 16 partial licences that will be upgraded — which should drive MRI volume, thereby increasing co's market share of MRIs by 183bp to 10.3% — brokerage
** All 13 analysts covering stock rate "buy" or higher; their median PT is A$3.10 — LSEG data
** Stock down 10% YTD, as of last close
(Reporting by Shivangi Lahiri in Bengaluru)
((shivangi.lahiri@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。